Collectively, our in vitro and in vivo loss-of-function and gain-of-function studies together with the patient data analysis suggest that SMARCD3 acts as the main driver in tumour metastatic dissemination in the evolution of MB. The gene discussed is SMARCD3; the disease is neoplasm.